All 1 tracked stories fall under one category: market-trends. Mirum Pharmaceuticals is most often covered alongside Alkermes, which appears in 1 of these 1 story. Source depth averages 20 original sources per story, versus 4.7 across the same-window beat baseline.
Figures are computed live from our source-verified story record
— see our methodology for how impact and
sentiment are derived.
What the coverage shows about Mirum Pharmaceuticals
All 1 tracked stories fall under one category: market-trends. Mirum Pharmaceuticals is most often covered alongside Alkermes, which appears in 1 of these 1 story. Source depth averages 20 original sources per story, versus 4.7 across the same-window beat baseline. Their average consequence score of 7 runs above the beat's 5.6 for that window. We currently track 1 Healthcare story that mention Mirum Pharmaceuticals, all published on February 26, 2026.
Stories tracked
1
Sources per story
20
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 41 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Appears alongside
Other entities that clear the same relevance threshold in stories also covering Mirum Pharmaceuticals. Shared-story counts are live from our verified record — not editorial picks.
The Q4 2025 earnings cycle for healthcare and health IT firms reveals a sector-wide shift toward AI-driven diagnostics and high-margin orphan drug commercialization. While medical device firms face cyclical equipment sales challenges, specialized biotech and diagnostic players like Veracyte and Soleno are reporting record profitability and rapid market penetration.
Mirum Pharmaceuticals is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source
link? Report a data issue.